Therapeutic Potential ImmunoScience, Inc. is advancing Contre Vir, a recombinant live attenuated vaccine aimed at HIV/AIDS treatment and potential cure, with multiple international patents and imminent Phase I trials, signaling strong positioning for partnerships with biotech manufacturers, contract research organizations, and clinical development service providers.

Clinical Expansion Preclinical success and pilot clinical results, plus planned Phase I trials in the US, Belgium, Ghana, and Uganda, indicate opportunities to engage trial site networks, regulatory consultants, and CROs to accelerate global clinical execution.

Funding Readiness Current revenue range suggests a growth stage with capital needs for manufacturing scale, regulatory filings, and late-stage development; potential for strategic investors, grant programs, and partnerships with larger biopharma for co-development or licensing.

Tech Enablement Diverse tech stack including React, jQuery, and modern web frameworks implies a readiness for digital engagement, data management, and partner portals; IT services and cybersecurity, cloud hosting, and software modernization vendors could add value.

Market Signals Strong interest across multiple countries and worldwide patent coverage highlight a competitive moat; sales conversations can focus on regulatory strategy support, manufacturing collaboration, and regional distribution or licensing opportunities with major players seeking HIV therapeutics.